Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Oncogenic pathways in hereditary and sporadic breast cancer.

Kenemans P, Verstraeten RA, Verheijen RH.

Maturitas. 2008 Sep-Oct;61(1-2):141-50.

PMID:
19434886
2.

Low vitamin B6 levels are associated with white matter lesions in Alzheimer's disease.

Mulder C, Scheltens P, Barkhof F, Gundy C, Verstraeten RA, de Leeuw FE.

J Am Geriatr Soc. 2005 Jun;53(6):1073-4. No abstract available.

PMID:
15935040
3.

Oncogenic pathways in hereditary and sporadic breast cancer.

Kenemans P, Verstraeten RA, Verheijen RH.

Maturitas. 2004 Sep 24;49(1):34-43. Review.

PMID:
15351094
4.

Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.

Davelaar EM, Schutter EM, von Mensdorff-Pouilly S, van Kamp GJ, Verstraeten RA, Kenemans P.

Ann Clin Biochem. 2003 Nov;40(Pt 6):663-73.

PMID:
14629806
5.

The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.

Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH.

Am J Obstet Gynecol. 2002 Aug;187(2):385-92.

PMID:
12193930
6.

T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.

Nijman HW, van Diest PJ, Poort-Keesom RJ, von Mensdorff-Pouilly S, Verstraeten RA, Kummer A, Meijer CJ, Melief CJ, Hilgers J, Kenemans P.

Eur J Obstet Gynecol Reprod Biol. 2001 Jan;94(1):114-20.

PMID:
11134836
7.

Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.

Ryuko K, Schol DJ, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Karuntu-Wanamarta YA, Verstraeten RA, Miyazaki K, Kenemans P, Hilgers J.

Tumour Biol. 2000 Jul-Aug;21(4):197-210.

PMID:
10867613
8.

Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.

Nijman HW, Kenemans P, Poort-Keesom RJ, Verstraeten RA, Mensdorff-Pouilly S, Verheijen RH, Melief CJ, Hilgers J, Meijer CJ.

Eur J Obstet Gynecol Reprod Biol. 1999 Apr;83(2):201-6.

PMID:
10391533
9.

Quantification of MUC1 in breast cancer patients. A method comparison study.

Bon GG, van Kamp GJ, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Kenemans P.

Eur J Obstet Gynecol Reprod Biol. 1999 Mar;83(1):67-75.

PMID:
10221613
10.

Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles.

Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ, Schoemaker J.

Hum Reprod. 1999 Feb;14(2):566-70.

PMID:
10100011
11.

Comparison of seven immunoassays for the quantification of CA 125 antigen in serum.

Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P.

Clin Chem. 1998 Jul;44(7):1417-22.

12.

'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence.

Schol DJ, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, Kenemans P, Hilgers J.

Tumour Biol. 1998;19 Suppl 1:35-45.

PMID:
9422087
13.

Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.

Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilgers J, et al.

Tumour Biol. 1998;19 Suppl 1:1-20. Review.

PMID:
9422084
14.

Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.

Vennegoor CJ, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Verheijen RH, Kast WM, Melief CJ, Kenemans P.

Cancer Lett. 1997 Jun 3;116(1):93-101.

PMID:
9177463
15.

Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays.

Bon GG, von Mensdorff-Pouilly S, Kenemans P, van Kamp GJ, Verstraeten RA, Hilgers J, Meijer S, Vermorken JB.

Clin Chem. 1997 Apr;43(4):585-93.

16.

Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.

Bonfrer JM, Korse CM, Verstraeten RA, van Kamp GJ, Hart GA, Kenemans P.

Clin Chem. 1997 Mar;43(3):491-7.

17.

Serum CA-125 concentrations during midfollicular phase, a clinically useful and reproducible marker in diagnosis of advanced endometriosis.

Hompes PG, Koninckx PR, Kennedy S, van Kamp GF, Verstraeten RA, Cornillie F.

Clin Chem. 1996 Nov;42(11):1871-4. No abstract available.

18.

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

Davelaar EM, Bonfrer JM, Verstraeten RA, ten Bokkel Huinink WW, Kenemans P.

Cancer. 1996 Jul 1;78(1):118-27.

PMID:
8646707
19.

Multicenter evaluation of the Abbott IMx CA 15-3 assay.

van Kamp GJ, Bon GG, Verstraeten RA, Lynch D, Krikau M, Fl├╝ckiger J, Ruibal A, Kenemans P.

Clin Chem. 1996 Jan;42(1):28-33.

20.
21.

Effect of hormones on the expression of proviral genes Mtv-2 and Mtv-3 in mouse mammary gland.

Sluyser M, Verstraeten RA, Van Nie R.

Int J Cancer. 1983 Feb 15;31(2):217-21.

PMID:
6298127

Supplemental Content

Loading ...
Support Center